Thomas C - Search Results

1

Early capsaicin intervention for neurogenic bladder in a rat model of spinal cord injury.

Thomas C, Kim JH, Torimoto K, Kwon DD, Kim YT, Tyagi P, Yoshimura N, Chancellor MB. Thomas C, et al. Biomed Res. 2007 Oct;28(5):255-9. doi: 10.2220/biomedres.28.255. Biomed Res. 2007. PMID: 18000338 Free article.

2

The overactive bladder: Epidemiology and morbidity.

Tyagi S, Thomas CA, Hayashi Y, Chancellor MB. Tyagi S, et al. Urol Clin North Am. 2006 Nov;33(4):433-8, vii. doi: 10.1016/j.ucl.2006.06.002. Urol Clin North Am. 2006. PMID: 17011378 Review.

3

The case for bladder botulinum toxin application.

Kim DK, Thomas CA, Smith C, Chancellor MB. Kim DK, et al. Among authors: thomas ca. Urol Clin North Am. 2006 Nov;33(4):503-10, ix. doi: 10.1016/j.ucl.2006.06.010. Urol Clin North Am. 2006. PMID: 17011386 Review.

4

The promise of beta3-adrenoceptor agonists to treat the overactive bladder.

Furuta A, Thomas CA, Higaki M, Chancellor MB, Yoshimura N, Yamaguchi O. Furuta A, et al. Urol Clin North Am. 2006 Nov;33(4):539-43, x. doi: 10.1016/j.ucl.2006.06.014. Urol Clin North Am. 2006. PMID: 17011390 Review.

5

Effect of hyperforin-enriched extract on pro-ejaculatory effect of 8-hydroxy-2-(di-N-propylamino)tetralin in anesthetized rats.

Thomas CA, Tyagi S, Yoshimura N, Chancellor MB, Tyagi P. Thomas CA, et al. Urology. 2007 Oct;70(4):813-6. doi: 10.1016/j.urology.2007.05.016. Urology. 2007. PMID: 17991578

6

Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.

Chuang YC, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. Chuang YC, et al. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Oct;19(10):1353-7. doi: 10.1007/s00192-008-0650-7. Epub 2008 May 27. Int Urogynecol J Pelvic Floor Dysfunct. 2008. PMID: 18504514

7

Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.

Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Tyagi P, et al. Int Braz J Urol. 2009 Jan-Feb;35(1):76-83. doi: 10.1590/s1677-55382009000100012. Int Braz J Urol. 2009. PMID: 19254402 Free article.

8

Botulinum-A toxin: an exciting new treatment option for prostatic disease.

Thomas CA, Guercini F, Chuang YC, Chancellor MB. Thomas CA, et al. Int J Clin Pract Suppl. 2006 Dec;(151):33-7. doi: 10.1111/j.1742-1241.2006.01180.x. Int J Clin Pract Suppl. 2006. PMID: 17169009 Review.

9

Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.

Thomas CA, Chuang YC, Giannantoni A, Chancellor MB. Thomas CA, et al. Curr Urol Rep. 2006 Jul;7(4):266-71. doi: 10.1007/s11934-996-0005-1. Curr Urol Rep. 2006. PMID: 16930497 Review.

10

(Z)-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane induces concentration-dependent growth inhibition, apoptosis, and coordinates regulation of apoptotic genes in TRAMP cells.

Thomas CA, Grant SG, Pflug BR, Getzenberg RH, Day BW. Thomas CA, et al. Urol Oncol. 2008 Jul-Aug;26(4):378-85. doi: 10.1016/j.urolonc.2007.02.013. Epub 2007 Dec 21. Urol Oncol. 2008. PMID: 18367102 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,657 results

Search Page

Filters